nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—Cerebellar ataxia—Cyclosporine—focal segmental glomerulosclerosis	0.132	0.156	CcSEcCtD
Raltegravir—Non-Hodgkin's lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.0228	0.0269	CcSEcCtD
Raltegravir—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.0228	0.0269	CcSEcCtD
Raltegravir—Renal tubular necrosis—Cyclosporine—focal segmental glomerulosclerosis	0.0223	0.0264	CcSEcCtD
Raltegravir—CCR1—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.0183	0.119	CbGpPWpGaD
Raltegravir—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.0173	0.0204	CcSEcCtD
Raltegravir—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.0173	0.0204	CcSEcCtD
Raltegravir—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.0148	0.0174	CcSEcCtD
Raltegravir—CCR1—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.0141	0.0915	CbGpPWpGaD
Raltegravir—Nephropathy toxic—Cyclosporine—focal segmental glomerulosclerosis	0.0139	0.0164	CcSEcCtD
Raltegravir—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.0135	0.016	CcSEcCtD
Raltegravir—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.0131	0.0155	CcSEcCtD
Raltegravir—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.0127	0.015	CcSEcCtD
Raltegravir—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.0122	0.0144	CcSEcCtD
Raltegravir—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.0119	0.0141	CcSEcCtD
Raltegravir—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.0119	0.0141	CcSEcCtD
Raltegravir—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.0114	0.0134	CcSEcCtD
Raltegravir—Hyperlipidaemia—Cyclosporine—focal segmental glomerulosclerosis	0.0111	0.0131	CcSEcCtD
Raltegravir—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.0106	0.0125	CcSEcCtD
Raltegravir—Gingivitis—Cyclosporine—focal segmental glomerulosclerosis	0.0101	0.012	CcSEcCtD
Raltegravir—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00933	0.011	CcSEcCtD
Raltegravir—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.0092	0.0109	CcSEcCtD
Raltegravir—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.009	0.0106	CcSEcCtD
Raltegravir—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.0102	CcSEcCtD
Raltegravir—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00864	0.0102	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.0086	0.056	CbGpPWpGaD
Raltegravir—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00859	0.0101	CcSEcCtD
Raltegravir—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.00797	0.00941	CcSEcCtD
Raltegravir—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00783	0.00925	CcSEcCtD
Raltegravir—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.00769	0.00909	CcSEcCtD
Raltegravir—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00752	0.00889	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—AGTR2—focal segmental glomerulosclerosis	0.00726	0.0472	CbGpPWpGaD
Raltegravir—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.0072	0.00851	CcSEcCtD
Raltegravir—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.00713	0.00842	CcSEcCtD
Raltegravir—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.00691	0.00817	CcSEcCtD
Raltegravir—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00678	0.00801	CcSEcCtD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00674	0.0438	CbGpPWpGaD
Raltegravir—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00665	0.00786	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00662	0.043	CbGpPWpGaD
Raltegravir—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.00652	0.00771	CcSEcCtD
Raltegravir—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00643	0.0076	CcSEcCtD
Raltegravir—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.00618	0.0073	CcSEcCtD
Raltegravir—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00615	0.00727	CcSEcCtD
Raltegravir—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00613	0.00724	CcSEcCtD
Raltegravir—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00608	0.00718	CcSEcCtD
Raltegravir—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.00595	0.00703	CcSEcCtD
Raltegravir—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.0059	0.00697	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00577	0.0375	CbGpPWpGaD
Raltegravir—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.00569	0.00673	CcSEcCtD
Raltegravir—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00569	0.00673	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00561	0.0365	CbGpPWpGaD
Raltegravir—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00548	0.00647	CcSEcCtD
Raltegravir—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00542	0.0064	CcSEcCtD
Raltegravir—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.0053	0.00626	CcSEcCtD
Raltegravir—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00528	0.00624	CcSEcCtD
Raltegravir—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00523	0.00617	CcSEcCtD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00518	0.0337	CbGpPWpGaD
Raltegravir—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00512	0.00605	CcSEcCtD
Raltegravir—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00503	0.00595	CcSEcCtD
Raltegravir—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00481	0.00568	CcSEcCtD
Raltegravir—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00479	0.00566	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00466	0.0303	CbGpPWpGaD
Raltegravir—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00465	0.00549	CcSEcCtD
Raltegravir—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00455	0.00537	CcSEcCtD
Raltegravir—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00452	0.00534	CcSEcCtD
Raltegravir—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00451	0.00533	CcSEcCtD
Raltegravir—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00446	0.00527	CcSEcCtD
Raltegravir—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00446	0.00527	CcSEcCtD
Raltegravir—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00444	0.00525	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00444	0.0289	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00439	0.0286	CbGpPWpGaD
Raltegravir—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00439	0.00519	CcSEcCtD
Raltegravir—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00438	0.00518	CcSEcCtD
Raltegravir—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00437	0.00516	CcSEcCtD
Raltegravir—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00437	0.00516	CcSEcCtD
Raltegravir—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00425	0.00502	CcSEcCtD
Raltegravir—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00421	0.00498	CcSEcCtD
Raltegravir—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.0042	0.00497	CcSEcCtD
Raltegravir—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.004	0.00473	CcSEcCtD
Raltegravir—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00398	0.0047	CcSEcCtD
Raltegravir—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00395	0.00467	CcSEcCtD
Raltegravir—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00393	0.00465	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.00393	0.0255	CbGpPWpGaD
Raltegravir—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00392	0.00463	CcSEcCtD
Raltegravir—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00386	0.00456	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00376	0.0245	CbGpPWpGaD
Raltegravir—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00373	0.00441	CcSEcCtD
Raltegravir—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00363	0.00429	CcSEcCtD
Raltegravir—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00361	0.00426	CcSEcCtD
Raltegravir—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00359	0.00424	CcSEcCtD
Raltegravir—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00354	0.00418	CcSEcCtD
Raltegravir—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0035	0.00414	CcSEcCtD
Raltegravir—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00348	0.00412	CcSEcCtD
Raltegravir—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00343	0.00405	CcSEcCtD
Raltegravir—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00341	0.00403	CcSEcCtD
Raltegravir—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00338	0.004	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00338	0.022	CbGpPWpGaD
Raltegravir—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00326	0.00386	CcSEcCtD
Raltegravir—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00323	0.00382	CcSEcCtD
Raltegravir—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00322	0.0038	CcSEcCtD
Raltegravir—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.0032	0.00378	CcSEcCtD
Raltegravir—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00314	0.00371	CcSEcCtD
Raltegravir—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00313	0.0037	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00312	0.0203	CbGpPWpGaD
Raltegravir—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00304	0.00359	CcSEcCtD
Raltegravir—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.00301	0.00355	CcSEcCtD
Raltegravir—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.0035	CcSEcCtD
Raltegravir—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.0035	CcSEcCtD
Raltegravir—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.0035	CcSEcCtD
Raltegravir—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00295	0.00349	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00294	0.00348	CcSEcCtD
Raltegravir—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00293	0.00346	CcSEcCtD
Raltegravir—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.0029	0.00343	CcSEcCtD
Raltegravir—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00287	0.00339	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00286	0.0186	CbGpPWpGaD
Raltegravir—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00282	0.00334	CcSEcCtD
Raltegravir—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00279	0.00329	CcSEcCtD
Raltegravir—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.00329	CcSEcCtD
Raltegravir—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00276	0.00326	CcSEcCtD
Raltegravir—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00275	0.00325	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00259	0.00306	CcSEcCtD
Raltegravir—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00257	0.00304	CcSEcCtD
Raltegravir—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00255	0.00302	CcSEcCtD
Raltegravir—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00253	0.00299	CcSEcCtD
Raltegravir—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.0025	0.00296	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.0025	0.0162	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00248	0.0162	CbGpPWpGaD
Raltegravir—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00247	0.00292	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00245	0.0029	CcSEcCtD
Raltegravir—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00245	0.0029	CcSEcCtD
Raltegravir—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00243	0.00287	CcSEcCtD
Raltegravir—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00243	0.00287	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00238	0.0155	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00235	0.0153	CbGpPWpGaD
Raltegravir—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00234	0.00277	CcSEcCtD
Raltegravir—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00232	0.00275	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00227	0.0148	CbGpPWpGaD
Raltegravir—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.00267	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00226	0.0147	CbGpPWpGaD
Raltegravir—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.00265	CcSEcCtD
Raltegravir—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00225	0.00265	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00216	0.014	CbGpPWpGaD
Raltegravir—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.00247	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00209	0.0136	CbGpPWpGaD
Raltegravir—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.00241	CcSEcCtD
Raltegravir—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00201	0.00238	CcSEcCtD
Raltegravir—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.0023	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00191	0.0124	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.0019	0.0123	CbGpPWpGaD
Raltegravir—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00188	0.00222	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.00182	0.0119	CbGpPWpGaD
Raltegravir—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00181	0.00214	CcSEcCtD
Raltegravir—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.00212	CcSEcCtD
Raltegravir—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.00212	CcSEcCtD
Raltegravir—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00178	0.0021	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00173	0.0113	CbGpPWpGaD
Raltegravir—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00169	0.00199	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00162	0.0105	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.00147	0.00956	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	0.00147	0.00953	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.00134	0.00874	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.00134	0.00872	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.00133	0.00867	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.00122	0.00794	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00112	0.00729	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.00102	0.00666	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000868	0.00565	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000843	0.00548	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000798	0.00519	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000721	0.00469	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000666	0.00433	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000582	0.00378	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000554	0.00361	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000425	0.00276	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.00035	0.00228	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000344	0.00224	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000303	0.00197	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	0.000279	0.00182	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—LPL—focal segmental glomerulosclerosis	0.00021	0.00137	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AGT—focal segmental glomerulosclerosis	0.00018	0.00117	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ALB—focal segmental glomerulosclerosis	0.000138	0.000897	CbGpPWpGaD
